The World of Dementia Beyond 2020
Identifieur interne : 006311 ( Main/Exploration ); précédent : 006310; suivant : 006312The World of Dementia Beyond 2020
Auteurs : Henry Brodaty [Belgique] ; Monique M. B. Breteler [Belgique] ; Steven T. Dekosky [Belgique] ; Pascale Dorenlot [Belgique] ; Laura Fratiglioni [Belgique] ; Christoph Hock [Belgique] ; Paul-Ariel Kenigsberg [Belgique] ; Philip Scheltens [Belgique] ; Bart De Strooper [Belgique]Source :
- Journal of the American Geriatrics Society [ 0002-8614 ] ; 2011-05.
Descripteurs français
- Pascal (Inist)
- Wicri :
English descriptors
- KwdEn :
- Adverse effects, Alzheimer, Alzheimer disease, Alzheimers dement, Amyloid, Amyloid pathway, Amyloid precursor protein, Apoe, Clinical effect phase, Clinical trials, Consulting fees, Current phase, Dementia, Dementia prevalence, Deposition inhibitor, Diabetes mellitus, Diagnosis, Dire projections, Drug development, Drug therapies, Elderly, Fondation, Fondation mederic alzheimer, Geriatrics, Gerontology, Global burden, Glycogen synthase, Henry brodaty, Immunization, Immunotherapy, Inhibitor, Lancet neurol, Late life, Literature searches, Medical research council, Molecular biology, Nancial relationships, Nerve growth factor, Neurimmune therapeutics, Neuropathology group, Oligomer aggregation, Passive immunotherapy, Peptide, Pharmaceutical industry, Pparg stimulant, Protective factors, Protein antibody, Public health, Receptor, Research centre, Scientific research, Societal costs, Study phase, Synthesis inhibitor, Treatment, Vascular risk factors, World.
- Teeft :
- Adverse effects, Alzheimer, Alzheimer disease, Alzheimers dement, Amyloid, Amyloid pathway, Amyloid precursor protein, Apoe, Clinical effect phase, Clinical trials, Consulting fees, Current phase, Dementia, Dementia prevalence, Deposition inhibitor, Diabetes mellitus, Dire projections, Drug development, Drug therapies, Fondation, Fondation mederic alzheimer, Global burden, Glycogen synthase, Henry brodaty, Immunization, Immunotherapy, Inhibitor, Lancet neurol, Late life, Literature searches, Medical research council, Molecular biology, Nancial relationships, Nerve growth factor, Neurimmune therapeutics, Neuropathology group, Oligomer aggregation, Passive immunotherapy, Peptide, Pharmaceutical industry, Pparg stimulant, Protective factors, Protein antibody, Receptor, Research centre, Societal costs, Study phase, Synthesis inhibitor, Vascular risk factors.
Abstract
Counterpoised against dire projections of the tripling of the prevalence of dementia over the next 40 years are major developments in diagnostic biomarkers, neuroimaging, the molecular biology of Alzheimer's disease (AD), epidemiology of risk and protective factors, and drug treatments—mainly targeting the amyloid pathway, tau protein, and immunotherapy—that may have the potential to modify the progression of AD. Drug combinations and presymptomatic treatments are also being investigated. Previous trials of dementia‐modifying drugs have not shown benefit, and even if current Phase III trials prove successful, these drugs will not eradicate other dementias, could (if not curative) increase dementia duration and prevalence, and are unlikely to come onto the market before 2020. In the meantime, delaying the onset of dementia by even 2 years would have significant economic and societal effects. This article provides an overview of current achievements and potentials of basic and clinical research that might affect the development of dementia prevalence and care within the near future.
Url:
DOI: 10.1111/j.1532-5415.2011.03365.x
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000985
- to stream Istex, to step Curation: 000985
- to stream Istex, to step Checkpoint: 000730
- to stream Main, to step Merge: 006687
- to stream PascalFrancis, to step Corpus: 001C46
- to stream PascalFrancis, to step Curation: 004297
- to stream PascalFrancis, to step Checkpoint: 001591
- to stream Main, to step Merge: 006A42
- to stream Main, to step Curation: 006311
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The World of Dementia Beyond 2020</title><author><name sortKey="Brodaty, Henry" sort="Brodaty, Henry" uniqKey="Brodaty H" first="Henry" last="Brodaty">Henry Brodaty</name></author><author><name sortKey="Breteler, Monique M B" sort="Breteler, Monique M B" uniqKey="Breteler M" first="Monique M. B." last="Breteler">Monique M. B. Breteler</name></author><author><name sortKey="Dekosky, Steven T" sort="Dekosky, Steven T" uniqKey="Dekosky S" first="Steven T." last="Dekosky">Steven T. Dekosky</name></author><author><name sortKey="Dorenlot, Pascale" sort="Dorenlot, Pascale" uniqKey="Dorenlot P" first="Pascale" last="Dorenlot">Pascale Dorenlot</name></author><author><name sortKey="Fratiglioni, Laura" sort="Fratiglioni, Laura" uniqKey="Fratiglioni L" first="Laura" last="Fratiglioni">Laura Fratiglioni</name></author><author><name sortKey="Hock, Christoph" sort="Hock, Christoph" uniqKey="Hock C" first="Christoph" last="Hock">Christoph Hock</name></author><author><name sortKey="Kenigsberg, Paul Riel" sort="Kenigsberg, Paul Riel" uniqKey="Kenigsberg P" first="Paul-Ariel" last="Kenigsberg">Paul-Ariel Kenigsberg</name></author><author><name sortKey="Scheltens, Philip" sort="Scheltens, Philip" uniqKey="Scheltens P" first="Philip" last="Scheltens">Philip Scheltens</name></author><author><name sortKey="De Strooper, Bart" sort="De Strooper, Bart" uniqKey="De Strooper B" first="Bart" last="De Strooper">Bart De Strooper</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:3532435BFD3EF646FC74FD62B25CB9AE4AC6283F</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1111/j.1532-5415.2011.03365.x</idno><idno type="url">https://api.istex.fr/document/3532435BFD3EF646FC74FD62B25CB9AE4AC6283F/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000985</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000985</idno><idno type="wicri:Area/Istex/Curation">000985</idno><idno type="wicri:Area/Istex/Checkpoint">000730</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000730</idno><idno type="wicri:doubleKey">0002-8614:2011:Brodaty H:the:world:of</idno><idno type="wicri:Area/Main/Merge">006687</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:11-0282174</idno><idno type="wicri:Area/PascalFrancis/Corpus">001C46</idno><idno type="wicri:Area/PascalFrancis/Curation">004297</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001591</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">001591</idno><idno type="wicri:doubleKey">0002-8614:2011:Brodaty H:the:world:of</idno><idno type="wicri:Area/Main/Merge">006A42</idno><idno type="wicri:Area/Main/Curation">006311</idno><idno type="wicri:Area/Main/Exploration">006311</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">The World of Dementia Beyond 2020</title><author><name sortKey="Brodaty, Henry" sort="Brodaty, Henry" uniqKey="Brodaty H" first="Henry" last="Brodaty">Henry Brodaty</name><affiliation wicri:level="1"><country xml:lang="fr">Belgique</country><wicri:regionArea>From the*Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia; †Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands, and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; ‡School of Medicine, University of Virginia, Charlottesville, Virginia; §Studies Department and **Economics, Finance and Prospective, Fondation Médéric Alzheimer, Paris, France; ∥Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden; #Division of Psychiatry Research, University of Zürich, Zurich, Switzerland; ††Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands; and ‡‡Center for Human Genetics, KU Leuven, and Department of Molecular and Developmental Genetics, VIB, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation></author><author><name sortKey="Breteler, Monique M B" sort="Breteler, Monique M B" uniqKey="Breteler M" first="Monique M. B." last="Breteler">Monique M. B. Breteler</name><affiliation wicri:level="1"><country xml:lang="fr">Belgique</country><wicri:regionArea>From the*Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia; †Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands, and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; ‡School of Medicine, University of Virginia, Charlottesville, Virginia; §Studies Department and **Economics, Finance and Prospective, Fondation Médéric Alzheimer, Paris, France; ∥Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden; #Division of Psychiatry Research, University of Zürich, Zurich, Switzerland; ††Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands; and ‡‡Center for Human Genetics, KU Leuven, and Department of Molecular and Developmental Genetics, VIB, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation></author><author><name sortKey="Dekosky, Steven T" sort="Dekosky, Steven T" uniqKey="Dekosky S" first="Steven T." last="Dekosky">Steven T. Dekosky</name><affiliation wicri:level="1"><country xml:lang="fr">Belgique</country><wicri:regionArea>From the*Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia; †Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands, and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; ‡School of Medicine, University of Virginia, Charlottesville, Virginia; §Studies Department and **Economics, Finance and Prospective, Fondation Médéric Alzheimer, Paris, France; ∥Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden; #Division of Psychiatry Research, University of Zürich, Zurich, Switzerland; ††Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands; and ‡‡Center for Human Genetics, KU Leuven, and Department of Molecular and Developmental Genetics, VIB, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation></author><author><name sortKey="Dorenlot, Pascale" sort="Dorenlot, Pascale" uniqKey="Dorenlot P" first="Pascale" last="Dorenlot">Pascale Dorenlot</name><affiliation wicri:level="1"><country xml:lang="fr">Belgique</country><wicri:regionArea>From the*Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia; †Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands, and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; ‡School of Medicine, University of Virginia, Charlottesville, Virginia; §Studies Department and **Economics, Finance and Prospective, Fondation Médéric Alzheimer, Paris, France; ∥Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden; #Division of Psychiatry Research, University of Zürich, Zurich, Switzerland; ††Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands; and ‡‡Center for Human Genetics, KU Leuven, and Department of Molecular and Developmental Genetics, VIB, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation></author><author><name sortKey="Fratiglioni, Laura" sort="Fratiglioni, Laura" uniqKey="Fratiglioni L" first="Laura" last="Fratiglioni">Laura Fratiglioni</name><affiliation wicri:level="1"><country xml:lang="fr">Belgique</country><wicri:regionArea>From the*Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia; †Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands, and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; ‡School of Medicine, University of Virginia, Charlottesville, Virginia; §Studies Department and **Economics, Finance and Prospective, Fondation Médéric Alzheimer, Paris, France; ∥Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden; #Division of Psychiatry Research, University of Zürich, Zurich, Switzerland; ††Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands; and ‡‡Center for Human Genetics, KU Leuven, and Department of Molecular and Developmental Genetics, VIB, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation></author><author><name sortKey="Hock, Christoph" sort="Hock, Christoph" uniqKey="Hock C" first="Christoph" last="Hock">Christoph Hock</name><affiliation wicri:level="1"><country xml:lang="fr">Belgique</country><wicri:regionArea>From the*Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia; †Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands, and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; ‡School of Medicine, University of Virginia, Charlottesville, Virginia; §Studies Department and **Economics, Finance and Prospective, Fondation Médéric Alzheimer, Paris, France; ∥Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden; #Division of Psychiatry Research, University of Zürich, Zurich, Switzerland; ††Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands; and ‡‡Center for Human Genetics, KU Leuven, and Department of Molecular and Developmental Genetics, VIB, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation></author><author><name sortKey="Kenigsberg, Paul Riel" sort="Kenigsberg, Paul Riel" uniqKey="Kenigsberg P" first="Paul-Ariel" last="Kenigsberg">Paul-Ariel Kenigsberg</name><affiliation wicri:level="1"><country xml:lang="fr">Belgique</country><wicri:regionArea>From the*Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia; †Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands, and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; ‡School of Medicine, University of Virginia, Charlottesville, Virginia; §Studies Department and **Economics, Finance and Prospective, Fondation Médéric Alzheimer, Paris, France; ∥Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden; #Division of Psychiatry Research, University of Zürich, Zurich, Switzerland; ††Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands; and ‡‡Center for Human Genetics, KU Leuven, and Department of Molecular and Developmental Genetics, VIB, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation></author><author><name sortKey="Scheltens, Philip" sort="Scheltens, Philip" uniqKey="Scheltens P" first="Philip" last="Scheltens">Philip Scheltens</name><affiliation wicri:level="1"><country xml:lang="fr">Belgique</country><wicri:regionArea>From the*Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia; †Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands, and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; ‡School of Medicine, University of Virginia, Charlottesville, Virginia; §Studies Department and **Economics, Finance and Prospective, Fondation Médéric Alzheimer, Paris, France; ∥Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden; #Division of Psychiatry Research, University of Zürich, Zurich, Switzerland; ††Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands; and ‡‡Center for Human Genetics, KU Leuven, and Department of Molecular and Developmental Genetics, VIB, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation></author><author><name sortKey="De Strooper, Bart" sort="De Strooper, Bart" uniqKey="De Strooper B" first="Bart" last="De Strooper">Bart De Strooper</name><affiliation wicri:level="1"><country xml:lang="fr">Belgique</country><wicri:regionArea>From the*Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia; †Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands, and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; ‡School of Medicine, University of Virginia, Charlottesville, Virginia; §Studies Department and **Economics, Finance and Prospective, Fondation Médéric Alzheimer, Paris, France; ∥Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden; #Division of Psychiatry Research, University of Zürich, Zurich, Switzerland; ††Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands; and ‡‡Center for Human Genetics, KU Leuven, and Department of Molecular and Developmental Genetics, VIB, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Journal of the American Geriatrics Society</title><title level="j" type="alt">JOURNAL OF AMERICAN GERIATRICS SOCIETY</title><idno type="ISSN">0002-8614</idno><idno type="eISSN">1532-5415</idno><imprint><biblScope unit="vol">59</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="923">923</biblScope><biblScope unit="page" to="927">927</biblScope><biblScope unit="page-count">5</biblScope><publisher>Blackwell Publishing Inc</publisher><pubPlace>Malden, USA</pubPlace><date type="published" when="2011-05">2011-05</date></imprint><idno type="ISSN">0002-8614</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0002-8614</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adverse effects</term><term>Alzheimer</term><term>Alzheimer disease</term><term>Alzheimers dement</term><term>Amyloid</term><term>Amyloid pathway</term><term>Amyloid precursor protein</term><term>Apoe</term><term>Clinical effect phase</term><term>Clinical trials</term><term>Consulting fees</term><term>Current phase</term><term>Dementia</term><term>Dementia prevalence</term><term>Deposition inhibitor</term><term>Diabetes mellitus</term><term>Diagnosis</term><term>Dire projections</term><term>Drug development</term><term>Drug therapies</term><term>Elderly</term><term>Fondation</term><term>Fondation mederic alzheimer</term><term>Geriatrics</term><term>Gerontology</term><term>Global burden</term><term>Glycogen synthase</term><term>Henry brodaty</term><term>Immunization</term><term>Immunotherapy</term><term>Inhibitor</term><term>Lancet neurol</term><term>Late life</term><term>Literature searches</term><term>Medical research council</term><term>Molecular biology</term><term>Nancial relationships</term><term>Nerve growth factor</term><term>Neurimmune therapeutics</term><term>Neuropathology group</term><term>Oligomer aggregation</term><term>Passive immunotherapy</term><term>Peptide</term><term>Pharmaceutical industry</term><term>Pparg stimulant</term><term>Protective factors</term><term>Protein antibody</term><term>Public health</term><term>Receptor</term><term>Research centre</term><term>Scientific research</term><term>Societal costs</term><term>Study phase</term><term>Synthesis inhibitor</term><term>Treatment</term><term>Vascular risk factors</term><term>World</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Diagnostic</term><term>Démence d'Alzheimer</term><term>Gériatrie</term><term>Gérontologie</term><term>Monde</term><term>Personne âgée</term><term>Recherche scientifique</term><term>Santé publique</term><term>Traitement</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>Adverse effects</term><term>Alzheimer</term><term>Alzheimer disease</term><term>Alzheimers dement</term><term>Amyloid</term><term>Amyloid pathway</term><term>Amyloid precursor protein</term><term>Apoe</term><term>Clinical effect phase</term><term>Clinical trials</term><term>Consulting fees</term><term>Current phase</term><term>Dementia</term><term>Dementia prevalence</term><term>Deposition inhibitor</term><term>Diabetes mellitus</term><term>Dire projections</term><term>Drug development</term><term>Drug therapies</term><term>Fondation</term><term>Fondation mederic alzheimer</term><term>Global burden</term><term>Glycogen synthase</term><term>Henry brodaty</term><term>Immunization</term><term>Immunotherapy</term><term>Inhibitor</term><term>Lancet neurol</term><term>Late life</term><term>Literature searches</term><term>Medical research council</term><term>Molecular biology</term><term>Nancial relationships</term><term>Nerve growth factor</term><term>Neurimmune therapeutics</term><term>Neuropathology group</term><term>Oligomer aggregation</term><term>Passive immunotherapy</term><term>Peptide</term><term>Pharmaceutical industry</term><term>Pparg stimulant</term><term>Protective factors</term><term>Protein antibody</term><term>Receptor</term><term>Research centre</term><term>Societal costs</term><term>Study phase</term><term>Synthesis inhibitor</term><term>Vascular risk factors</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Gérontologie</term><term>Industrie pharmaceutique</term><term>Personne âgée</term><term>Recherche scientifique</term><term>Santé publique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Counterpoised against dire projections of the tripling of the prevalence of dementia over the next 40 years are major developments in diagnostic biomarkers, neuroimaging, the molecular biology of Alzheimer's disease (AD), epidemiology of risk and protective factors, and drug treatments—mainly targeting the amyloid pathway, tau protein, and immunotherapy—that may have the potential to modify the progression of AD. Drug combinations and presymptomatic treatments are also being investigated. Previous trials of dementia‐modifying drugs have not shown benefit, and even if current Phase III trials prove successful, these drugs will not eradicate other dementias, could (if not curative) increase dementia duration and prevalence, and are unlikely to come onto the market before 2020. In the meantime, delaying the onset of dementia by even 2 years would have significant economic and societal effects. This article provides an overview of current achievements and potentials of basic and clinical research that might affect the development of dementia prevalence and care within the near future.</div></front></TEI><affiliations><list><country><li>Belgique</li></country></list><tree><country name="Belgique"><noRegion><name sortKey="Brodaty, Henry" sort="Brodaty, Henry" uniqKey="Brodaty H" first="Henry" last="Brodaty">Henry Brodaty</name></noRegion><name sortKey="Breteler, Monique M B" sort="Breteler, Monique M B" uniqKey="Breteler M" first="Monique M. B." last="Breteler">Monique M. B. Breteler</name><name sortKey="De Strooper, Bart" sort="De Strooper, Bart" uniqKey="De Strooper B" first="Bart" last="De Strooper">Bart De Strooper</name><name sortKey="Dekosky, Steven T" sort="Dekosky, Steven T" uniqKey="Dekosky S" first="Steven T." last="Dekosky">Steven T. Dekosky</name><name sortKey="Dorenlot, Pascale" sort="Dorenlot, Pascale" uniqKey="Dorenlot P" first="Pascale" last="Dorenlot">Pascale Dorenlot</name><name sortKey="Fratiglioni, Laura" sort="Fratiglioni, Laura" uniqKey="Fratiglioni L" first="Laura" last="Fratiglioni">Laura Fratiglioni</name><name sortKey="Hock, Christoph" sort="Hock, Christoph" uniqKey="Hock C" first="Christoph" last="Hock">Christoph Hock</name><name sortKey="Kenigsberg, Paul Riel" sort="Kenigsberg, Paul Riel" uniqKey="Kenigsberg P" first="Paul-Ariel" last="Kenigsberg">Paul-Ariel Kenigsberg</name><name sortKey="Scheltens, Philip" sort="Scheltens, Philip" uniqKey="Scheltens P" first="Philip" last="Scheltens">Philip Scheltens</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006311 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 006311 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:3532435BFD3EF646FC74FD62B25CB9AE4AC6283F
|texte= The World of Dementia Beyond 2020
}}
| This area was generated with Dilib version V0.6.33. |  |